<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840472</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-58398</org_study_id>
    <secondary_id>ENT0083</secondary_id>
    <nct_id>NCT04840472</nct_id>
  </id_info>
  <brief_title>Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer</brief_title>
  <official_title>Pilot Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to assess the safety of 111In-panitumumab as a molecular&#xD;
      imaging agent in patients with Head and Neck Squamous Cell Carcinoma.&#xD;
&#xD;
      The secondary objective is to compare sensitivity and specificity of identifying sentinel&#xD;
      lymph nodes by systemic injection of 111In-panitumumab prior to Day of Surgery versus&#xD;
      conventional local injection with an optical dye at the time of surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Logistics&#xD;
  </why_stopped>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety of 111In panitumumab as a molecular imaging agent in patients with HNSCC.</measure>
    <time_frame>15 days</time_frame>
    <description>Number of CTCAE v5.0 Grade 2 or higher adverse events by Day 15 determined that are significant, definitely or probably related to 111In panitumumab. Safety data will be summarized by grade, severity, and type.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare sensitivity of systemic 111In panitumumab versus conventional local optical dye</measure>
    <time_frame>10 days after surgery</time_frame>
    <description>Sensitivity of systemic 111In panitumumab of identifying sentinel lymph nodes versus sensitivity of conventional local optical dye in identifying sentinel lymph nodes using histopathology will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare specificity of systemic 111In panitumumab versus conventional local optical dye</measure>
    <time_frame>10 days after surgery</time_frame>
    <description>Specificity of systemic 111In panitumumab of identifying sentinel lymph nodes versus specificity of conventional local optical dye in identifying sentinel lymph nodes using histopathology will be compared</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>111-In panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug (111In panitumumab) 5 mCi, allowable range 4.5 to 5.5 will be administered on Day 0, and subjects will undergo one 111In panitumumab SPECT/CT imaging anytime between Day 1 and Day of Surgery. Subjects will undergo surgical resection after infusion of 111In panitumumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111I-n panitumumab</intervention_name>
    <description>Imaging Agent</description>
    <arm_group_label>111-In panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single photon emission computed tomography/computed tomography (SPECT/CT) scans</intervention_name>
    <description>Day 1 to 5 (Day of Surgery inclusive)</description>
    <arm_group_label>111-In panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.&#xD;
&#xD;
          -  Subjects diagnosed with any T stage, any subsite within the head and neck that are&#xD;
             scheduled to undergo surgical resection. Subjects with recurrent disease or a new&#xD;
             primary will be allowed.&#xD;
&#xD;
          -  Planned standard of care elective neck dissection for a cN0 or cN1 disease. Clinical&#xD;
             N1 disease will be defined as metastasis in a single, ipsilateral lymph node, 3 cm or&#xD;
             less in greatest dimension by clinical exam, cross sectional imaging or metabolic&#xD;
             imaging.&#xD;
&#xD;
          -  Have acceptable hematologic status, coagulation status, kidney function, and liver&#xD;
             function including the following clinical results:&#xD;
&#xD;
          -  Hemoglobin ≥ 9 gm/dL&#xD;
&#xD;
          -  White blood cell count &gt; 3000/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times upper reference range&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive&#xD;
             heart failure (CHF); significant liver disease; or unstable angina within 6 months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  History of infusion reactions to monoclonal antibody therapies.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Magnesium or potassium lower than the normal institutional values.&#xD;
&#xD;
          -  Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,&#xD;
             amiodarone, sotalol) antiarrhythmic agents.&#xD;
&#xD;
          -  Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.&#xD;
&#xD;
          -  Severe renal disease or anuria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Baik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Universiy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

